Redeye initiates coverage of AcouSort, a Swedish medtech company aiming to introduce its unique acoustofluidic technology in the automation of the sample preparation process in diagnostics, analytics, and cell therapy manufacturing. Our base case suggests a significant upside potential in the share, and we argue that the main catalysts to close the valuation gap are further progress with its partners and accelerating sales from OEM components.